Watching Shares Of Catalent; Traders Circulate RBC Note Saying Catalent Should Be 'Up Big On Regeneron FDA Approval
Portfolio Pulse from Benzinga Newsdesk
Traders are circulating a note from RBC suggesting that Catalent should see a significant increase following the FDA approval of Regeneron. This is likely due to Catalent's involvement in the production of Regeneron's products.
August 18, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Catalent's stock is expected to rise significantly following the FDA approval of Regeneron, as suggested by a note from RBC.
Catalent is involved in the production of Regeneron's products. Therefore, the FDA approval of Regeneron is likely to have a positive impact on Catalent's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Regeneron has received FDA approval, which is likely to have a positive impact on its stock.
The FDA approval is a significant milestone for Regeneron, which is likely to boost investor confidence and, in turn, its stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100